D&A at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s D&A?
- Monte Rosa Therapeutics, Inc. (GLUE) reported D&A of $2.03M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s D&A changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s D&A decreased by 0.9% year-over-year, from $2.05M to $2.03M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s D&A has grown at a 41.5% compound annual growth rate (CAGR), from $2.08M to $8.36M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.